The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Save

Report Abuse

Description

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Study Overview

Start Date
July 1, 2022
Completion Date
July 1, 2024
Enrollment
147
Date Posted
May 4, 2022
Accepts Healthy Volunteers?
No
Gender
All

Locations

Full Address
Central Chest Institute of Thailand
Nonthaburi, Mueang Nonthaburi District 11000, Thailand

Eligibility

Minimum Age (years)
18
Eligibility Criteria
Inclusion Criteria:

post AKI stage 2-3
CrCl > 20

Exclusion Criteria:

pregnancy
post kidney transplant
previous use of SGLT2 Inhibitors
history of ketoacidosis

Study Contact Info

Study Contact Name
Sasipha Tachaboon
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
NCTid (if applicable)
NCT05360615